Instil Bio, Inc.
TILNASDAQHealthcare● Active
$8.08
+$0.01(+0.12%)
Market Cap$54798366
P/E Ratio—
52W High$42.79
52W Low$5.67
Instil Bio, Inc. (TIL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TIL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.62
Est. -$0.62 · +0.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
TIL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.35 | — | — | — | — | — |
| — Q2 FY2026 | May 15, 2026 | -$0.62 | -$0.62 | +0.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 27, 2026 | -$2.31 | -$1.21 | +47.6% | — | $0.00B | — |
| — Q4 FY2025 | Nov 13, 2025 | -$2.00 | -$2.01 | -0.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$1.72 | -$3.24 | -88.4% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$2.02 | -$4.32 | -113.9% | — | — | — |
| ▲ Q1 FY2025 | Mar 4, 2025 | -$3.75 | -$1.82 | +51.5% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$2.08 | -$3.54 | -70.2% | — | $0.00B | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.35
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026
EPS Actual
-$0.62
EPS Est.
-$0.62
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 27, 2026Beat
EPS Actual
-$1.21
EPS Est.
-$2.31
EPS Surpr.
+47.6%
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
-$2.01
EPS Est.
-$2.00
EPS Surpr.
-0.5%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$3.24
EPS Est.
-$1.72
EPS Surpr.
-88.4%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$4.32
EPS Est.
-$2.02
EPS Surpr.
-113.9%
Revenue
—
Q1 FY2025
Mar 4, 2025Beat
EPS Actual
-$1.82
EPS Est.
-$3.75
EPS Surpr.
+51.5%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$3.54
EPS Est.
-$2.08
EPS Surpr.
-70.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2026 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q2 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q1 FY2026 | $-0.59 | $-0.59 | $-0.59 | 1 |
| Q4 FY2025 | $-2.04 | $-2.04 | $-2.04 | 1 |
| Q3 FY2025 | $-2.35 | $-2.35 | $-2.35 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +0.0% | $8.05 | $8.07 | +0.25% |
| ▲ Q1 FY2026 | Mar 27, 2026 | +47.6% | $8.36 | $7.79 | -6.82% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -0.5% | $14.99 | $13.91 | -7.20% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -88.4% | $26.83 | $26.97 | +0.52% |
| ▼ Q2 FY2025 | May 13, 2025 | -113.9% | $13.68 | $12.74 | -6.87% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +51.5% | $18.28 | $17.50 | -4.27% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -70.2% | $33.38 | $31.54 | -5.51% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +24.7% | $10.58 | $10.35 | -2.17% |
Q2 FY2026+0.25%
Report Date
May 15, 2026
EPS Beat/Miss
+0.0%
Price Before
$8.05
Price After
$8.07
Q1 FY2026-6.82%
Report Date
Mar 27, 2026
EPS Beat/Miss
+47.6%
Price Before
$8.36
Price After
$7.79
Q4 FY2025-7.20%
Report Date
Nov 13, 2025
EPS Beat/Miss
-0.5%
Price Before
$14.99
Price After
$13.91
Q3 FY2025+0.52%
Report Date
Aug 13, 2025
EPS Beat/Miss
-88.4%
Price Before
$26.83
Price After
$26.97
Q2 FY2025-6.87%
Report Date
May 13, 2025
EPS Beat/Miss
-113.9%
Price Before
$13.68
Price After
$12.74
Q1 FY2025-4.27%
Report Date
Mar 4, 2025
EPS Beat/Miss
+51.5%
Price Before
$18.28
Price After
$17.50
Q4 FY2024-5.51%
Report Date
Nov 13, 2024
EPS Beat/Miss
-70.2%
Price Before
$33.38
Price After
$31.54
Q3 FY2024-2.17%
Report Date
Aug 13, 2024
EPS Beat/Miss
+24.7%
Price Before
$10.58
Price After
$10.35
Avg Beat Reaction-4.04%
Avg Miss Reaction-3.95%
Beat Rate5 / 8 quarters
Largest Move-7.20% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TIL ends December
Instil Bio, Inc. (TIL) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.62 (in line with the analyst consensus of $-0.62). TIL has beaten EPS estimates for 2 consecutive quarters. The next TIL earnings date is expected around September 1, 2026.
Each quarter, investors track TIL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TIL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TIL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TIL earnings · 4 questionsInstil Bio, Inc.'s next earnings report is expected around September 1, 2026. TIL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TIL historically reports after market close (AMC).
TIL earnings datewhen is TIL earningsTIL next earnings datewhen does TIL report earningsTIL earnings calendar
▸ Source: FMP · Instil Bio, Inc. SEC filings · US GAAP · Instil Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026